Monogram Orthopaedics (NASDAQ:MGRM – Get Free Report ) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report ) are both healthcare companies, but which stock is the better buy? We compare the two businesses based on analyst recommendations, profitability, institutional holdings, risk, dividends, valuation and earnings strength.
Analyst Recommendations
Here’s a breakdown of current valuations and target prices for Monogram Orthopaedics and Tandem Diabetes Care from MarketBeat.com.
| Sell rating | Ratings on hold | Purchase Rating | Strong Buy Rating | Evaluation score | |
| Monogram Orthopedics | 0 | 0 | 0 | 0 | N/A |
| Tandem Diabetes Care | 0 | 1 | 12 | 0 | 2.92 |
The consensus price target for Tandem Diabetes Care is $51.25, suggesting an upside potential of 19.19%. Given Tandem Diabetes Care’s higher upside potential, analysts clearly see Tandem Diabetes Care as a better bet than Monogram Orthopedics.
Revenue and Ratings
This table compares the revenue, earnings per share, and valuation of Monogram Orthopaedics and Tandem Diabetes Care.
| Earnings | Price/Sales Ratio | Net income | Earnings per Share | Price Earnings Ratio | |
| Monogram Orthopedics | $370,000.00 | 168.62 | -$13.74 million | ($0.50) | -3.94 |
| Tandem Diabetes Care | $747.72 million | 3.71 | -$222.61 million | ($2.17) | -19.82 |
Monogram Orthopedics has higher profits but lower sales than Tandem Diabetes Care. Tandem Diabetes Care trades at a lower price-to-earnings multiple than Monogram Orthopedics, making Tandem Diabetes Care the more affordable of the two stocks right now.
Institutional and insider ownership
Institutional investors own 0.5% of Monogram Orthopedics’ shares. Insiders own 32.1% of Monogram Orthopedics’ shares. In comparison, insiders own 2.2% of Tandem Diabetes Care’s shares. Strong institutional ownership suggests that endowments, hedge funds, and large asset managers believe the company is poised for long-term growth.
Profitability
This table compares the net profit margins, return on equity, and return on assets of Monogram Orthopaedics and Tandem Diabetes Care.
| Net income | Return on Equity | Return on Assets | |
| Monogram Orthopedics | N/A | -112.33% | -78.71% |
| Tandem Diabetes Care | -18.37% | -34.38% | -10.91% |
summary
Monogram Orthopedics outperforms Tandem Diabetes Care in 7 of the 12 factors comparing the two brands.
About Monogram Orthopedics
(Get your free report)
Monogram Orthopaedics, Inc. is focused on developing product solution architectures that enable patient-optimized orthopedic implants. The company plans to manufacture and sell robotic surgical instruments and associated software for use in reconstructive joint replacement surgery, orthopedic implants, tissue ablation tools, navigation consumables, and various other instruments. The company’s robotic prototypes execute optimized paths for highly accurate insertion of optimized implants into synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.
About Tandem Diabetes Care
(Get your free report)
Tandem Diabetes Care, Inc., a medical device manufacturer, designs, develops, and commercializes technology solutions for people with diabetes in the United States and worldwide. The company’s flagship products are the t:slim X2 insulin delivery system, a pump platform that manages insulin delivery and displays continuous glucose monitoring sensor information directly on the pump’s home screen, and the Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells disposable products, such as cartridges for storing and delivering insulin and infusion sets that connect the insulin pump to the user’s body. In addition, the company offers Tandem Device Updater, which is used to update pump software from a personal computer; Tandem Source, a web-based data management platform that visually displays diabetes care management data from pumps, integrated CGMs, and supported glucose meters; and Sugarmate, a mobile app that visualizes diabetes care data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Receive daily Monogram Plastic Surgery news and reviews –Enter your email address below to receive a concise summary of the latest news and analyst ratings on Monogram Orthopaedics and related companies every day via MarketBeat.com’s free email newsletter.
